Ahmad Golestanifar, Arezo Masroor, Hengameh Khedri, Mohammadreza Saberiyan, Azim Nejatizadeh
{"title":"Integrative analysis of lncRNAs in rheumatoid arthritis: from bioinformatics to experimental validation.","authors":"Ahmad Golestanifar, Arezo Masroor, Hengameh Khedri, Mohammadreza Saberiyan, Azim Nejatizadeh","doi":"10.1007/s10238-025-01589-z","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and systemic inflammation. Despite advances in treatment, challenges persist in early diagnosis and personalized therapy. Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators in immune pathways and inflammation, offering potential as diagnostic biomarkers and therapeutic targets. Using GEO datasets (GSE169082, GSE124373), we identified differentially expressed genes in peripheral blood mononuclear cells of RA patients. Functional enrichment and pathway analyses were conducted to elucidate their roles. Key lncRNAs (LINC00963, SNHG15, SNHG3) were experimentally validated via real-time PCR in patient samples. Protein-protein interaction networks and ceRNA networks were constructed to explore molecular interactions. Analysis revealed significant up-regulation of LINC00963, SNHG15, and SNHG3 in RA patients, correlating with inflammatory markers and immune cell profiles. ROC analysis demonstrated high diagnostic potential, particularly for SNHG3 (AUC: 84.3%). Pathway enrichment highlighted immune activation and disrupted autophagic processes. This study identifies novel lncRNAs with diagnostic and therapeutic potential in RA, emphasizing the integration of computational and experimental approaches. These findings lay the groundwork for precision medicine strategies to improve RA management.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"64"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839865/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01589-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and systemic inflammation. Despite advances in treatment, challenges persist in early diagnosis and personalized therapy. Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators in immune pathways and inflammation, offering potential as diagnostic biomarkers and therapeutic targets. Using GEO datasets (GSE169082, GSE124373), we identified differentially expressed genes in peripheral blood mononuclear cells of RA patients. Functional enrichment and pathway analyses were conducted to elucidate their roles. Key lncRNAs (LINC00963, SNHG15, SNHG3) were experimentally validated via real-time PCR in patient samples. Protein-protein interaction networks and ceRNA networks were constructed to explore molecular interactions. Analysis revealed significant up-regulation of LINC00963, SNHG15, and SNHG3 in RA patients, correlating with inflammatory markers and immune cell profiles. ROC analysis demonstrated high diagnostic potential, particularly for SNHG3 (AUC: 84.3%). Pathway enrichment highlighted immune activation and disrupted autophagic processes. This study identifies novel lncRNAs with diagnostic and therapeutic potential in RA, emphasizing the integration of computational and experimental approaches. These findings lay the groundwork for precision medicine strategies to improve RA management.
期刊介绍:
Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.